FTRE1 Stock Chart & Stats
$373.00
$0.00(0.00%)
At close: 4:00 PM EDT
$373.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$373.00 - $373.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$27.41B
Enterprise Value$2.60K
Total Cash (Recent Filing)$168.60M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Nov 05, 2026EPS Estimate
3.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding95,100,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$371.67Price Target Upside-0.36% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)14.27
Revenue Forecast (FY)$45.21B
Bulls Say, Bears Say
Bulls Say
Commercial MomentumStrong bookings and a large backlog provide multi-quarter revenue visibility for Fortrea’s outsourced clinical development model. Four consecutive quarters with book-to-bill above 1.0x and 19% first-half award growth indicate improving demand and support future study execution.
Cash Generation And DeleveragingPositive operating and free cash flow give Fortrea internal resources to fund operations while reducing reliance on external financing. Continued cash generation, combined with substantial debt repayment and lower interest expense, can gradually improve liquidity and financial flexibility.
Clinical Pharmacology ExpansionThe proposed acquisition would add a Clinical Pharmacology Unit and bioanalytical laboratory operations to Fortrea’s CPS business. Expanding specialized early-phase capabilities could strengthen service breadth, improve customer continuity, and support growth as the transaction integrates.
Bears Say
Persistent UnprofitabilityOngoing GAAP losses and materially compressed gross margins weaken the durability of Fortrea’s earnings base. Even with improving adjusted results, lower underlying profitability leaves less capacity to absorb execution pressures, invest for growth, or accelerate balance-sheet repair.
Elevated LeverageHigh leverage remains a structural constraint because a greater share of operating resources may need to support debt obligations rather than growth or investment. It also limits flexibility if profitability recovery slows, making sustained cash generation important for further deleveraging.
Customer ConcentrationHeavy dependence on a small group of customers increases the business impact of any major account slowdown, repricing, or lost program. Concentration can make revenue and utilization less predictable and may weaken Fortrea’s negotiating position with its largest sponsors.
Fortrea Holdings Inc. News
FTRE1 FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $373.00 and its highest was $373.00 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $27.41B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 55 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Jul 29, 2026. The company reported $3.915 earnings per share for the quarter, beating the consensus estimate of $3.064 by $0.851.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Overvalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 3.64.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 95,100,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $3.915 in its last earnings report, beating expectations of $3.064. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in MX:FTRE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$371.67 (-0.36% Downside)
$371.67 (-0.36% Downside)
Blogger Sentiment
Bullish
MX:FTRE1 Sentiment 67%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
FTRE1 Company Deck
FTRE1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial commercial momentum (bookings up, net new business +19% H1), improved profitability metrics (adjusted EBITDA growth, cost savings, SG&A reduction), stronger cash generation and an upgraded full-year guidance, alongside early operational wins from FIT/AI and CPS strength. Key risks discussed include a modest YoY revenue decline driven by pass-through/FSP dynamics, elevated customer concentration, a CFO transition related to a restrictive covenant matter, and the early-stage nature of AI benefits. On balance, the positive operational, commercial and financial traction and the guidance raise outweigh the listed challenges.View all MX:FTRE1 earnings summariesFTRE1 Stock 12 Month Forecast
Average Price Target
$371.67
▼(-0.36% Downside)
Technical Analysis
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
MBX Biosciences, Inc.
―
Generate Biomedicines, Inc.
―